Tech Times

CRISPR Cas9 Genome Editing Explained: Designer Babies Ethical Dilemmas & DNA Ethics

CRISPR Cas9 gene therapy explained with DNA scissors, hereditary diseases treatment, and designer babies ethical dilemmas ...
Open Access Government

Targeting βiii-Tubulin and the roots of science: An interview with Richard F. Ludueña

Professor Emeritus Richard F. Ludueña discusses his novel theoretical framework for cancer chemotherapy, utilising ...
The Scientist

From Discovery to Cure: How CRISPR Came of Age

Trace the timeline of CRISPR-Cas9 from its 2012 discovery to the latest AI-driven advancements and "N-of-1" clinical ...

Here’s What Analysts Are Saying About CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, ...
IPWatchdog

PTAB Upholds Priority Win for Broad Institute in CRISPR Patent Case

On remand from the Federal Circuit, the Patent Trial and Appeal Board on Thursday reaffirmed its decision that The Broad ...
Morning Overview on MSN

RNA-guided CRISPR tool turns genes on with dose control

Researchers have built a series of CRISPR-based platforms that can switch endogenous genes on and, just as critically, dial ...
The Print on MSN

Scientists who won the Nobel for CRISPR gene editing just lost a patent war — again

A US patent board last week backed the Broad Institute’s claim to CRISPR use in human and animal cells, not the Nobel winners ...

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office ...